Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity.

Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9432572 Publication Model: Print Cited Medium: Print ISSN: 1350-1925 (Print) Linking ISSN: 13501925 NLM ISO Abbreviation: Neurogastroenterol Motil Subsets: MEDLINE

Original Publication: Osney Mead, Oxford, UK : Blackwell Scientific Publications, c1994-

Gastrointestinal Diseases/*drug therapy ; Gastrointestinal Tract/*drug effects ; Pain Threshold/*drug effects ; Serotonin/*metabolism ; Visceral Afferents/*drug effects; Animals ; Cyclooxygenase 2 Inhibitors/therapeutic use ; Gastrointestinal Diseases/genetics ; Gastrointestinal Diseases/physiopathology ; Gastrointestinal Tract/physiology ; Humans ; Probiotics/therapeutic use ; Receptors, Serotonin/drug effects ; Serotonin Agents/therapeutic use ; Serotonin Antagonists/therapeutic use

Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors.

261

0 (Cyclooxygenase 2 Inhibitors)
0 (Receptors, Serotonin)
0 (Serotonin Agents)
0 (Serotonin Antagonists)
333DO1RDJY (Serotonin)

Date Created: 20070207 Date Completed: 20070504 Latest Revision: 20131121

20231215

10.1111/j.1365-2982.2006.00876.x

17280587